Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates

Molecules

Volumn 13, Issue 2, 2008, Pages 360-378

  Leonelli, Francesca ^a   La Bella, Angela ^a   Migneco, Luisa Maria ^a   Bettolo, Rinaldo Marini ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biological activity; Hyaluronic acid; Hyaluronic acid paclitaxel bioconjugate; Paclitaxel; Synthesis

Indexed keywords

ANTINEOPLASTIC AGENT; HYALURONIC ACID; PACLITAXEL;

ANIMAL; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; HUMAN; REVIEW; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYALURONIC ACID; PACLITAXEL;

EID: 40349098590     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules13020360     Document Type: Review

References (122)

1. Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. Plant antitumor agents. VI. Isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325-2327.
2. Perez, E.A. Paclitaxel in breast cancer. Oncologist 1998, 3, 373-389.
3. Gibbs, J.B. Mechanism-based target identification and drug discovery in cancer research. Science 2000, 287, 1969-1973.
4. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4, 253-265.
5. Markman, M. Weekly paclitaxel in the management of ovarian cancer. Semin. Oncol. 2000, 27, 37-40.
6. Seiden, M.V. Ovarian Cancer, Oncologist 2001, 6, 327-332.
7. Singla, A.K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm. 2002, 235, 179-192.
8. Denis, J.-N.; Greene, A.E.; Guénard, D.; Guéritte- Voegelein, F.; Mangatal, L.; Potier, P. Highly efficient, practical approach to natural Taxol. J. Am. Chem. Soc. 1988, 110, 5917-5919.
9. Holton, R.A. Method for preparation of Taxol. Eur. Pat. Appl. 1990, EP 400971.
10. Patel, R.N. Tour de Paclitaxel: biocatalysis for semisynthesis. Annu. Rev. Microbiol. 1998, 52, 361-395.
11. Galletti, E.; Magnani, M.; Renzulli, M.L.; Botta, M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2007, 2, 920-942.
12. Szebeni, J.; Muggia, F.M.; Alving, C.R. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. 1998, 90, 300-306.
13. Thigpen, J.T. Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin. Oncol. 2000, 27, 11-16.
14. Knemeyer, I.; Wientjes, M.G.; Au, J.L.-S. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother. Pharmacol. 1999, 44, 241-248.
15. Gelderblom, H.; Verweij, J.; Van Zomeren, D. M.; Buijs, D.; Ouwens, L.; Nooter, K.; Stoter, G.; Sparreboom, A. Influence of Cremophor EL on the bioavailability of intraperitoneal paclitaxel. Clin. Cancer Res. 2002, 8, 1237-1241.
16. Laurent, T.C.; Laurent, U.B.; Fraser, J.R. Functions of hyaluronan. Ann. Rheum. Dis. 1995, 54, 429-432.
17. Misra, S.; Toole, B.P.; Ghatak, S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J. Biol. Chem. 2006, 281, 34936-34941.
18. Ohno, S.; Im, H.-J.; Knudson, C.B.; Knudson, W. Hyaluronic oligosaccharides induce matrix metalloproteinase 13 via transcriptional activation of NFkB and p38 MAP kinase in articular chondrocytes. J. Biol. Chem. 2006, 281, 17952-17960.
19. Rooney, P.; Kumar, S.; Ponting, J.; Wang, M. The role of hyaluronan in tumour neovascularization (review). Int. J. Cancer 1995, 60, 632-636.
20. Akima, K.; Ito, H.; Iwata, Y.; Matsuo, K.; Watari, N.; Yanagi, M.; Hagi, H.; Oshima, K.; Yagita, A.; Atomi, Y.; Tatekawa, I. Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. J. Drug Target. 1996, 4, 1-8.
21. Jaracz, S.; Chen, J.; Kuznetsova L.V.; Ojima, I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005, 13, 5043-5054.
22. Pawar, R.; Shikanov, A.; Vaisman, B.; Domb, A.J. Intravenous and regional paclitaxel formulations. Curr. Med. Chem. 2004, 11, 397-402.
23. Kim, T.-Y.; Kim, D.-W.; Chung, J.-Y.; Shin, S.G.; Kim, S.-C.; Heo, D.S.; Kim, N.K.; Bang, Y.-J. Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 2004, 10, 3708-3716.
24. Wang, Y. Tocosol® paclitaxel. Anticancer formulation. Drugs Fut. 2006, 31, 40-42.
25. Henderson, I.C.; Bhatia, V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Exp. Rev. Anticancer Ther. 2007, 7, 919-943.
26. Skwarczynki, M.; Hayashi, Y.; Kiso, Y. Paclitaxel prodrugs: toward smarter delivery anticancer agents. J. Med. Chem. 2006, 49, 7253-7269, and references cited therein
27. Greenwald, R.B.; Pendri, A.; Bolikal, D.; Gilbert, C.W. Highly water soluble taxol derivatives: 2′-polyethylene glycol esters as potential prodrugs. Bioorg. Med. Chem. Lett. 1994, 4, 2465-2470.
28. Greenwald, R.B.; Pendri, A.; Bolikal, D. Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates. J. Org. Chem. 1995, 60, 331-336.
29. Li, C.; Yu, D.; Inoue, T.; Yang, D.J.; Milas, L.; Hunter, N.R.; Kim, E.E.; Wallace, S. Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anticancer Drugs 1996, 7, 642-648.
30. Greenwald, R.B.; Gilbert, C.W.; Pendri, A.; Conover, C.D.; Xia, J.; Martinez, A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 1996, 39, 424-431.
31. Pendri, A.; Conover, C.D.; Greenwald, R.B. Antitumor activity of paclitaxel-2′-glycinate conjugate to poly(ethylene glycol): a water soluble prodrug. Anticancer Drug Des. 1998, 13, 387-395.
32. Ceruti, M.; Crosasso, P.; Brusa, P.; Arpicco, S.; Dosio, F.; Cattel. L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J. Controlled Release 2000, 63, 141-153.
33. Feng, X.; Yuan, Y.-J.; Wu, J.-C. Synthesis and evaluation of water-soluble paclitaxel prodrugs. Bioorg. Med. Chem. Lett. 2002, 12, 3301-3303.
34. Rodrigues, P.C.; Scheuermann, K.; Stockmar, C.; Maier, G.; Fiebig, H.H.; Unger, C.; Mülhaupt, R.; Kratz, F. Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg. Med. Chem. Lett. 2003, 13, 355-360.
35. Zhang, X.; Li, Y.; Chen, X.; Wang, X.; Xu, X.; Liang, Q.; Hu, J.; Jing, X. Synthesis and characterization of the paclitaxel/MPEG-PLA block copolymer conjugate. Biomaterials 2005, 26, 2121-2128.
36. Khandare, J.J.; Jayant, S.; Singh, A.; Chandna, P.; Wang, Y.; Vorsa, N.; Minko, T. Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconj. Chem. 2006, 17, 1464-1472.
37. Wermeckes, B.; Hess, M.; Dehne, S.; Jo, B.-W.; Sohn, J.-S. Characterization of PEG-modified paclitaxel. Mater. Res. Innov, 2006, 10, 364-375.
38. Kratz, F.; Abu Ajai, K.; Warnecke, A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Invest. Drugs 2007, 16, 1037-1058.
39. Xie, Z.; Lu, T.; Chen, X.; Lu, C.; Zheng, Y.; Jing, X. Triblock poly(lactic acid)-b-poly(ethylene glycol)-b-poly(lactic acid)/paclitaxel conjugates: synthesis, micellization, and cytotoxicity. J. Appl. Polym. Sci. 2007, 105, 2271-2279.
40. Xie, Z.; Guan, H.; Chen, X.; Lu, C.; Chen, L.; Hu, X.; Shi, Q.; Jing, X. A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. J. Controlled Release 2007, 117, 210-216.
41. Lim, J.; Simanek, E.E. Synthesis of water-soluble dendrimers based on melamine bearing 16 paclitaxel groups. Org. Lett. 2008, 10, 201-204.
42. Mendichi, R.; Rizzo, V.; Gigli, M.; Giacometti Schieroni, A. Dilute-solution properties of a polymeric antitumor drug carrier by size-exclusion chromatography, viscometry, and light scattering. J. Appl. Polym. Sci. 1998, 70, 329-338.
43. Meerum Terwogt, J.M.; ten Bokkel Huinink, W.W.; Schellens, J.H.M.; Schot, M.; Mandjes, I.A.M.; Zurlo, M.G.; Rocchetti, M.; Rosing, H.; Koopman, F.J.; Beijnen, J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs 2001, 12, 315-323.
44. Duncan, R.; Gac-Breton, S.; Keane, R.; Musila, R.; Sat, Y.N.; Satchi, R.; Searle, F. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Controlled Release 2001, 74, 135-146.
45. Rihova, B.; Kubackova, K. Clinical implications of N-(2-hydroxypropyl) methacrylamide copolymers. Curr. Pharm. Biotechnol. 2003, 4, 311-322.
46. Haag, R.; Kratz, F. Polymer Therapeutics: concept and applications. Angew. Chem. Int. Ed. 2006, 45, 1198-1215.
47. Sugahara, S.; Kajiki, M.; Kuriyama, H.; Kobayashi, T. Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. Biol. Pharm. Bull. 2002, 25, 632-641.
48. Multani, A.S.; Li, C.; Ozen, M.; Yadav, M.; Yu, D.-F.; Wallace, S.; Pathak, S. Paclitaxel and water-soluble poly(L-glutamic acid)-paclitaxel induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line. Anticancer Res. 1997, 17, 4269-4274.
49. Li, C.; Yu, D.-F.; Newman, R.A.; Cabral, F.; Stephens, L.C.; Hunter, N.; Milas, L.; Wallace, S. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 1998, 58, 2404-2409.
50. Li, C.; Price, J.E.; Milas, L.; Hunter, N.R.; Ke, S.; Yu, D.-F.; Charnsangavej, C.; Wallace, S. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin. Cancer Res. 1999, 5, 891-897.
51. Multani, A.S.; Li, C.; Ozen, M.; Imam, A.S.; Wallace, S.; Pathak, S. Cell-killing by paclitaxel in a metastatic murine melanoma cell line is mediated by extensive telomere erosion with no decrease in telomerase activity. Oncol. Rep. 1999, 6, 39-44.
52. Li, C.; Newman, R.A.; Wu, Q.-P.; Ke, S.; Chen, W.; Hutto, T.; Kan, Z.; Brannan, M.D.; Charnsangavej, C.; Wallace, S. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother. Pharmacol. 2000, 46, 416-422.
53. Li, C.; Ke, S.; Wu, Q.P.; Tansey, W.; Hunter, N.; Buchmiller, L.M.; Milas, L.; Charnsangavej, C.; Wallace, S. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin. Cancer Res. 2000, 6, 2829-2834.
54. Oldham, E.A.; Li, C.; Ke, S.; Wallace, S.; Huang, P. Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. Int. J. Oncol. 2000, 16, 125-132.
55. Li, C.; Ke, S.; Wu, Q.-P.; Tansey, W.; Hunter, N.; Buchmiller, L.M.; Milas, L.; Charnsangavej, C.; Wallace, S. Potentiation of ovarian OCA-1 tumor radioresponse by poly(L-glutamic acid)-paclitaxel conjugate. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 1119-1126.
56. Ke, S.; Milas, L.; Charnsangavej, C.; Wallace, S.; Li, C. Potentiation of radioresponse by polymer-drug conjugates. J. Controlled Release 2001, 74, 237-242.
57. Auzenne, E.; Donato, N.J.; Li, C.; Leroux, E.; Price, R.E.; Farquhar, D.; Klostergaard, J. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with Taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin. Cancer Res. 2002, 8, 573-581.
58. Singer, J.W.; Baker, B.; de Vries, P.; Kumar, A.; Shaffer, S.; Vawter, E.; Bolton, M.; Garzone, P. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 2003, 519, 81-99.
59. Milas, L.; Mason, K.A.; Hunter, N.; Li, C.; Wallace, S. Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys. 2003, 55, 707-712.
60. Tishler, R.B. Polymer-conjugated paclitaxel as a radiosensitizing agent-A big step forward for combined modality therapy? Int. J. Radiation Oncology Biol. Phys. 2003, 55, 563-564.
61. Zou, Y.; Fu, H.; Ghosh, S.; Farquhar, D.; Klostergaard, J. Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin. Cancer Res. 2004, 10, 7382-7391.
62. Sabbatini, P.; Aghajanian, C.; Dizon, D.; Anderson, S.; Dupont, J.; Brown, J.V.; Peters, W.A.; Jacobs, A.; Mehdi, A.; Rivkin, S.; Eisenfeld, A.J.; Spriggs, D. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 2004, 22, 4523-4531.
63. Singer, J.W.; Shaffer, S.; Baker, B.; Bernareggi, A.; Stromatt, S.; Nienstedt, D.; Besman, M. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anti-Cancer Drugs 2005, 16, 243-254.
64. Nemunaitis, J.; Cunningham, C.; Senzer, N.; Gray, M.; Oldham, F.; Pippen, J.; Mennel, R.; Eisenfeld, A. Phase I Study of CT-2103, A polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest. 2005, 23, 671-676.
65. Singer, J.W. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J. Controlled Release 2005, 109, 120-126.
66. Chipman, S.D.; Oldham, F.B.; Pezzoni, G.; Singer, J.W. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int. J. Nanomed. 2006, 1, 375-383.
67. Lee, K.H.; Chung, Y.J.; Kim, Y.C.; Song, S.J. Anti-tumor activity of paclitaxel prodrug conjugated with polyethylene glycol. Bull. Kor. Chem. Soc. 2005, 26, 1079-1082.
68. Lee, Y. Preparation and characterization of folic acid linked poly(L-glutamate)nanoparticles for cancer targeting. Macromol. Res. 2006, 14, 387-393.
69. Dipetrillo, T.; Milas, L.; Evans, D.; Akerman, P.; Ng, T.; Miner, T.; Cruff, D.; Chauhan, B.; Iannitti, D.; Harrington, D.; Safran, H. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study. Am. J. Clin. Oncol. 2006, 29, 376-379.
70. Albain, K.S.; Belani, C.P.; Bonomi, P.; O'Byrne, K.J.; Schiller, J.H.; Socinski, M. Pioneer: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naïve women with advanced-stage non small-cell lung cancer and performance status of 2. Clin. Lung Canc. 2006, 7, 417-419.75.
71. Jackson, E.F:; Esparza-Coss, E.; Wen, X.; Ng, C.S.; Daniel, S.L.; Price, R.E.; Rivera, B.; Charnsangavej, C.; Gelovani, J.G.; Li, C. Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68, 830-838.
72. Boddy, A.V. Paclitaxel poliglumex: antimitotic drug oncolytic. Drugs Fut. 2007, 32, 776-780.
73. Bonomi, P. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther. 2007, 7, 415-422.
74. Papas, S.; Akoumianaki, T.; Kalogiros, C.; Hadjiarapoglou, L.; Theodoropoulos, P.A.; Tsikaris, V. Synthesis and antitumor activity of peptide-paclitaxel conjugates. J. Pept. Sci. 2007, 13, 662-671.
75. Kumar, S.K.; Williams, S.A.; Isaacs, J.T.; Denmeade, S.R.; Khan, S.R. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg. Med. Chem. 2007, 15, 4973-4984.
76. Dosio, F.; Brusa, P.; Crosasso, P.; Arpicco, S.; Cattel, L. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J. Controlled Release 1997, 47, 293-304.
77. Bicamumpaka, C.; Page, M. In vitro cytotoxicity of paclitaxel-transferrin conjugate on H69 cells. Oncol. Rep. 1998, 5, 1381-1383.
78. Dosio, F.; Arpicco, S.; Brusa, P.; Stella, B.; Cattel, L. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. J. Controlled Release 2001, 76, 107-117.
79. de Groot, F.M.H.; Albrecht, C.; Koekkoek, R.; Beusker, P.H.; Scheeren, H.W. "Cascade-release dendrimers" liberate all end groups upon a single triggering event in the dendritic core. Angew. Chem. Int. Edit. Engl. 2003, 42, 4490-4494.
80. Majoros, I.J.; Myc, A.; Thomas, T.; Mehta, C.B.; Baker, J.R., PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006, 7, 572-579.
81. Luo, Y.; Prestwich, G.D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconj. Chem. 1999, 10, 755-763.
82. Luo, Y.; Ziebell, M.R.; Prestwich, G.D. A Hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromol. 2000, 1, 208-218.
83. Marini Bettolo, R.; Migneco, L.M.; De Luca, G. Taxane covalently bounded to hyaluronic acid or hyaluronic acid derivatives. PCT Int. Appl. Patent No. WO2004035629, 2004.
84. Capodilupo, A.L.; Crescenzi, V.; Francescangeli, A.; Joudioux, R.; Leonelli, F.; Marini Bettolo, R.; Migneco, L.M.; Quagliariello, M.; Bellato, P.; De Luca, G.; Galbiati, E.; Renier, D.; Banzato, A.; Rosato, A. Hydrosoluble, Metabolically Fragile Bioconjugates By Coupling Tetrabutylammonium Hyaluronan with 2′Paclitaxel-4-Bromobutyrate: Synthesis and Antitumor Properties In "Hyaluronan 2003" Hyaluronan Structure, Metabolism, Biological Activities, Therapeutic Applications, Balazs, E.A.; Hascall, V.C., Eds.; Matrix Biology Institute: New Jersey, 2005; Vol. I, pp. 391-395.
85. Leonelli, F.; La Bella, A.; Francescangeli, A.; Joudioux, R.; Capodilupo, A.-L.; Quagliariello, M.; Migneco, L.M.; Marini Bettolo, R.; Crescenzi, V.; De Luca G.; Renier, D. A new and simply available class of hydrosoluble bioconjugates by coupling paclitaxel to hyaluronic acid through a 4-hydroxybutanoic acid derived linker. Helv. Chim. Acta. 2005, 88, 154-159.
86. Thierry, B.; Kujawa, P.; Tkaczyk, C.; Winnik, F.M.; Bilodeau, L.; Tabrizian, M. Delivery platform for hydrophobic drugs: prodrug approach combined with self assembled multilayers. J. Am. Chem. Soc. 2005, 127, 1626-1627.
87. Maeda, H.; Seymour, L.W.; Miyamoto, Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. 1992, 3, 351-362.
88. Vincent, M.J.; Duncan, R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2006, 24, 39-47.
89. Luo, Y.; Prestwich, G.D. Cancer targeted polymeric drugs. Curr. Cancer Drug Targets 2002, 2, 209-226.
90. Mellado, W.; Magri, N.F.; Kingstone, D.G.I.; Garcia-Arenas, R.; Orr, G.A.; Horwitz, S.B. Preparation and biological activity of taxol acetates. Biochem. Biophys. Res. Commun. 1984, 124, 329-336.
91. Magri, N.F.; Kingston, D.G.I. Modified taxols, 4. Synthesis and biological activity of taxols modified in the side chain. J. Nat. Prod. 1988, 51, 298-306.
92. Souto, A.A.; Acuna, A.U.; Andreu, J.M.; Barasoain, I.; Abal, M.; Amat-Guerri, F. New fluorescent water-soluble taxol derivatives. Angew. Chem. Int. Ed. Engl. 1996, 34, 2710-2712.
93. Rose, W.C.; Clark, J.L.; Lee, F.Y.F.; Casazza, A.M. Preclinical antitumor activity of watersoluble paclitaxel derivatives. Cancer Chemother. Pharmacol. 1997, 39, 486-492.
94. Harada, N.; Ozaki, K.; Yamaguchi, T.; Hiroaki, A.; Ando, A.; Oda, K.; Nakanishi, N.; Ohashi, M.; Hashiyama, T.; Tsujihara, K. Synthesis of taxoids II. Synthesis and antitumor activity of water-soluble taxoids. Heterocycles 1997, 46, 241-258.
95. 14C]-labelled and fluorescent-tagged paclitaxel derivatives as new biological probes. Bioorg. Med. Chem. 1998, 6, 2193-2204.
96. Bhat, L.; Liu, Y.; Victory, S.F.; Himes, R.H.; Georg, G.I.; Synthesis and evaluation of paclitaxel C7 derivatives: solution phase synthesis of combinatorial libraries. Bioorg. Med. Chem. Lett. 1998, 8, 3181-3186.
97. Jagtap, P.G.; Baloglu, E.; Barron, D.M.; Bane, S.; Kingston, D.G.I. Design and synthesis of a combinatorial chemistry library of 7-acyl, 10-acyl, and 7,10-diacyl analogues of paclitaxel (taxol) using solid phase synthesis. J. Nat. Prod. 2002, 65, 1136-1142.
98. El Alaoui, A.; Schmidt, F.; Monneret, C.; Florent, J.-C. Protecting groups for glucuronic acid: application to the synthesis of new paclitaxel (taxol) derivatives. J. Org. Chem. 2006, 71, 9628-9636.
99. Forrest, M.L.; Yanez, J.A.; Remsberg, C.M.; Ohgami, Y.; Kwon, G.S.; Davies, NM. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(ε-caprolactone) micelle nanocarriers: pharmacokinetics disposition, tolerability, and cytotoxicity. Pharm. Res. 2008, 25, 194-206.
100. Pouyani,T.; Prestwich, G.D. Functionalized derivatives of hyaluronic acid oligosaccharides-drug carriers and novel biomaterials. Bioconj. Chem. 1994, 5, 339-347.
101. Pouyani,T.; Harbison, G.S.; Prestwich, G.D. Novel hydrogels of hyaluronic acid: synthesis, surface morphology, and solid state NMR. J. Am. Chem. Soc. 1994, 116, 7515-7522.
102. Vercruysse, K.P.; Marecak, D.M.; Marecek, J.F.; Prestwich, G.D. Synthesis and in vitro degradation of new polyvalent hydrazide cross-linked hydrogels of hyaluronic acid. Bioconjug. Chem. 1997, 8, 686-694.
103. Klostergaard and co-workers [105] prepared bioconjugate 3 basically according to Prestwich and co-workers method [82-83], but using pH 8.5 in final coupling, which gives a better yield.
104. Auzenne, E.; Ghosh, S.C.; Khodadadian, M.; Rivera, B.; Farquhar, D.; Price, R.E.; Ravoori, M.; Kundra, V.; Freedman, R.S.; Klostergaard, J. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007, 9, 479-486.
105. Rosato, A.; Banzato, A.; De Luca, G.; Renier, D.; Bettella, F.; Pagano, C.; Esposito, G.; Zanovello, P.; Bassi, P. HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol. Oncol.-Semin. Ori. 2006, 24, 207-215.
106. 99mTc-ONCOFID-P] in mice using four different administration routes. J. Labelled Compd. Radiopharm. 2006, 49, 939-950.
107. Sukhishvili, S.A. Layered, erasable polymer multilayers formed by hydrogen-bonded sequential self-assembly. Macromolecules 2002, 35, 301-310.
108. Chung, A.J.; Rubner, M.F. Methods of loading and releasing low molecular weight cationic molecules in weak polyelecrolyte multilayer films. Langmuir 2002, 18, 1176-1183.
109. Vázquez, E.; Dewitt, D.M.; Hammond, P.T.; Lynn, D.M. Construction of hydrolytically-degradable thin films via layer-by-layer deposition of degradable polyelectrolytes. J. Am. Chem. Soc. 2002, 124, 13992-13993.
110. Hiller, J.; Rubner, M.F. Reversible molecular memory and pH-switchable swelling transitions in polyelectrolyte multilayers. Macromolecules 2003, 36, 4078-4083.
111. Shchukin, D.G.; Patel, A.A.; Sukhorukov, G.B.; Lvov, Y.M. Nanoassembly of biodegradable microcapsules for DNA encasing. J. Am. Chem. Soc. 2004, 126, 3374-3375.
112. Peyratout, C.S.; Dähne, L. Tailor-made polyelectrolyte microcapsules: from multilayers to smart containers. Angew. Chem. Int. Ed. 2004, 43, 3762-3783.
113. Jackson, J.K.; Skinner, K.C.; Burgess, L.; Sun, T.; Hunter, W.L.; Burt, H.M. Paclitaxel-loaded crosslinked hyaluronic acid films for the prevention of postsurgical adhesions. Pharm. Res. 2002, 19, 411-417.
114. Yin, D.; Ge, Z.; Yang, W.; Liu, C.; Yuan, Y. Inhibition of tumor metastasis in vivo by combination of paclitaxel and hyaluronic acid. Cancer Lett. 2006, 243, 71-79.
115. Tezcaner, A.; Hicks, D.; Boulmedais, F.; Sahel, J.; Schaaf, P.; Voegel, J.-C.; Lavalle P. Polyelectrolyte multilayer films as substrates for photoreceptor cells. Biomacromolecules 2006, 7, 86-94.
116. Vodouhê, C.; Schmittbuhl, M; Boulmedais, F.; Bagnard, D.; Vautier, D.; Schaaf, P.; Egles, C.; Voegel, J.-C.; Ogier, J. Effect of functionalization of multilayered polyelectrolyte films on motoneuron growth. Biomaterials 2005, 26, 545-554.
117. Jessel, N.; Atalar, F.; Lavalle, P.; Mutterer, J.; Decher, G.; Schaaf, P.; Voegel, J.-C.; Ogier, J. Bioactive coatings based on polyelectrolyte multilayer architecture functionalized by embedded proteins. Adv. Mater. 2003, 15, 692-695.
118. Chluba, J.; Voegel, J.-C.; Decher, G.; Erbacher, P.; Schaaf, P.; Ogier, J. Peptide hormone covalently bound to polyelectrolytes and embedded into multilayer architectures conserving full biological activity. Biomacromolecules 2001, 2, 800-805.
119. Caruso, F.; Schüler, C. Enzyme multilayers on colloid particles: assembly, stability, and enzymatic activity. Langmuir 2000, 16, 9595-9603.
120. Caruso, F.; Niikura, K.; Furlong, D.N.; Okahata Y. Assembly of alternating polyelectrolyte and protein multilayer films for immunosensing. Langmuir 1997, 13, 3427-3433.
121. Vodouhê, C.; Le Guen, E.; Garza, J.M.; Francius, G.; Déjugnat, C.; Ogier, J.; Schaaf, P.; Voegel, J.-C.; Lavalle, P. Control of drug accessibility on functional polyelectrolyte multilayer films. Biomaterials 2006, 27, 4149-4156.
122. Kidambi, S.; Lee, I.; Chan, C. Controlling primary hepatocyte adhesion and spreading on protein-free polyelectrolyte multilayer films. J. Am. Chem. Soc. 2004, 126, 16286-16287.